Jason Wiles Email

VP, Discovery and Preclinical Sciences . Avilar Therapeutics

Current Roles

Employees:
32
Revenue:
$2.5M
About
Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degrader therapeutics that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC-mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA.
Avilar Therapeutics Address
400 Totten Pond Road
Waltham, MA
Avilar Therapeutics Email

Past Companies

Avilar TherapeuticsVice President, Discovery and Preclinical Sciences
Avilar TherapeuticsVice President, Preclinical Development
Alexion Pharmaceuticals, Inc.Senior Director, Small Molecule Research - Chemistry & Drug Metabolism and Pharmacokinetics

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.